Emergent Biosolutions Inc (EBS) concluded trading on Thursday at a closing price of $5.94, with 6.18 million shares of worth about $36.7 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 143.44% during that period and on September 25, 2024 the price saw a loss of about -2.78%. Currently the company’s common shares owned by public are about 52.20M shares, out of which, 51.72M shares are available for trading.
Stock saw a price change of -13.91% in past 5 days and over the past one month there was a price change of -36.27%. Year-to-date (YTD), EBS shares are showing a performance of 147.50% which increased to 87.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.42 but also hit the highest price of $15.10 during that period. The average intraday trading volume for Emergent Biosolutions Inc shares is 3.13 million. The stock is currently trading -21.12% below its 20-day simple moving average (SMA20), while that difference is down -36.09% for SMA50 and it goes to 18.90% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Emergent Biosolutions Inc (NYSE: EBS) currently have 52.20M outstanding shares and institutions hold larger chunk of about 56.41% of that.
The stock has a current market capitalization of $320.88M and its 3Y-monthly beta is at 1.59. It has posted earnings per share of -$11.25 in the same period. It has Quick Ratio of 0.54 while making debt-to-equity ratio of 2.27. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EBS, volatility over the week remained 8.05% while standing at 9.39% over the month.
Stock’s fiscal year EPS is expected to rise by 67.74% while it is estimated to increase by 101.49% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on August 22, 2024 offering a Buy rating for the stock and assigned a target price of $16 to it. Coverage by The Benchmark Company stated Emergent Biosolutions Inc (EBS) stock as a Buy in their note to investors on March 07, 2024, suggesting a price target of $5 for the stock. Stock get a Buy rating from The Benchmark Company on April 10, 2023.
